InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,490.00
(
-0.24%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
0.00%
)
Bitcoin
69,391.35
(
0.09%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jb_118 post# 1060

Monday, 04/02/2007 2:30:57 AM

Monday, April 02, 2007 2:30:57 AM

Post# of 19309
Roche Acquires Therapeutic Human Polyclonals Inc. for $56.5M

[THP is a private U.S.-based company that was cited in a 2006 Nature Biotechnology article on polyclonal antibodies (#msg-13789275, bottom). In my opinion, polyclonal antibodies are a questionable idea from a business standpoint for the reasons mentioned in #msg-13789631. Perhaps that’s why Roche is buying the company so cheaply even though this PR says that THP also has expertise in monoclonal antibodies.]

http://biz.yahoo.com/bw/070402/20070401005044.html?.v=1

>>
Monday April 2, 1:30 am ET

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Roche, the world's largest biotechnology company, has acquired privately held biopharmaceutical company Therapeutic Human Polyclonals Inc. for $56.5 million.

THP, a California-based company with a subsidiary in Germany, is focused on research in human antibody technologies. The company has developed a unique transgenic mammalian platform to create human antibodies. The technology will enable the generation of both monoclonal and polyclonal antibody therapeutics with enhanced efficacy. [A little more color would be helpful here, but THP is private and Roche generally plays its cards close to the vest.]

The acquisition of THP strengthens Roche's expertise in therapeutic antibody research. Roche is a global leader in therapeutic antibodies with its cancer therapies MabThera®, Herceptin® and Avastin®. Roche plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research organization in Penzberg, Germany.

"Co-founder Roland Buelow and I are delighted that Roche will be taking THP's human antibody platform to the next stage," said THP co-founder and chief executive officer Wim Van Schooten. "Roche is the ideal company for furthering development of this technology."

Van Schooten and Buelow founded THP to develop and commercialize next-generation human antibody therapies with initial funding and incubation from Research Corporation Technologies Inc. in Tucson, Ariz. In 2002, SangStat Medical Corp. (acquired by Genzyme Corporation in Cambridge, Mass.) joined RCT in continuing to fund development of THP's novel antibody platform.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up